LB253

Nebraska LB253 would mandate insurance and Medicaid coverage for biomarker testing.

Nebraska LB253 aims to ensure insurance and Medicaid coverage for biomarker testing. The bill requires health insurers, nonprofit health service plans, and health maintenance organizations to cover biomarker testing starting January 1, 2026. Coverage applies to diagnosis, treatment, management, or monitoring of diseases or conditions supported by medical and scientific evidence. The bill also mandates timely approval or denial of prior authorization requests and establishes a process for exceptions to coverage policies or adverse prior authorization determinations.